CanSino Biologics (HKG:6185, SHA:688185) obtained a priority review status from the Center for Drug Evaluation of the National Medical Products Administration of China for its combined vaccine for infants, a Friday bourse filing said.
The company had applied for a new drug application for its absorbed diphtheria, tetanus, and acellular pertussis combined vaccine, DTcP, for infants below 2 years old.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。